CBIO vs RVMD
CBIO: A clinical-stage oncology biotech developing a PD-1 x VEGF bispecific antibody backbone and a portfolio of antibody-drug conjugates to treat solid tumors. RVMD: Revolution Medicines is a precision oncology company developing targeted therapies to treat RAS-addicted cancers through its proprietary research platform.
Side-by-side fundamentals
| Metric | CBIO | RVMD | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $16.43 | $197.81 | |
| Market cap as of 2026-08-08 | $610M | $42.4B | |
| PEG as of 2026-08-08 | n/a | -0.23 | |
| Net margin as of 2026-08-08 | -990.3% | -2833.9% | CBIO higher |
| Gross margin as of 2026-08-08 | -0.5% | n/a | |
| Operating margin as of 2026-08-08 | -978.0% | -3145.0% | CBIO higher |
| ROE as of 2026-08-08 | -102.1% | -54.1% | RVMD higher |
| ROA as of 2026-08-08 | -89.3% | -39.1% | RVMD higher |
| Debt / equity as of 2026-08-08 | 0.00 | 0.19 | CBIO lower |
| Revenue growth (YoY) as of 2026-08-08 | +413.7% | n/a | |
| Beta as of 2026-08-08 | 1.28 | 1.40 | |
| 1-year return as of 2026-08-06 close | +49.4% | +439.4% | RVMD higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.